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Background: Immune monitoring by flow cytometry is a fast and highly informative way of studying the effects of
novel therapeutics aimed at reducing transplant rejection or treating autoimmune diseases. The ONE Study
consortium has recently initiated a series of clinical trials aimed at using different cell therapies to promote
tolerance to renal allografts. To compare the effectiveness of different cell therapies, the consortium developed a
robust immune monitoring strategy, including procedures for whole blood (WB) leukocyte subset profiling by flow
cytometry.
Methods: Six leukocyte profiling panels computing 7- to 9-surface marker antigens for monitoring the major
leukocyte subsets as well as characteristics of T cell, B cell, and dendritic cell (DC) subsets were designed. The
precision and variability of these panels were estimated. The assay was standardized within eight international
laboratories using Flow-Set Pro beads for mean fluorescence intensity target definition and the flow cytometer
setup procedure. Standardization was demonstrated by performing inter-site comparisons.
Results: Optimized methods for sample collection, storage, preparation, and analysis were established, including
protocols for gating target subsets. WB specimen age testing demonstrated that staining must be performed within
4 hours of sample collection to keep variability low, meaning less than or equal to 10% for the majority of defined
leukocyte subsets. Inter-site comparisons between all participating centers testing shipped normal WB revealed
good precision, with a variability of 0.05% to 30% between sites. Intra-assay analyses revealed a variability of 0.05%
to 20% for the majority of subpopulations. This was dependent on the frequency of the particular subset, with
smaller subsets showing higher variability. The intra-assay variability performance defined limits of quantitation
(LoQ) for subsets, which will be the basis for assessing statistically significant differences achieved by the different
cell therapies.
Conclusions: Local performance and central analysis of the ONE Study flow cytometry panel yields acceptable
variability in a standardized assay at multiple international sites. These panels and procedures with WB allow
unmanipulated analysis of changes in absolute cell numbers of leukocyte subsets in single- or multicenter clinical
trials. Accordingly, we propose the ONE Study panel may be adopted as a standardized method for monitoring
patients in clinical trials enrolling transplant patients, particularly trials of novel tolerance promoting therapies, to
facilitate fair and meaningful comparisons between trials.
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Immune monitoring by flow cytometry is crucial in
studying effects of novel therapeutics aimed at modula-
ting the immune response. The ONE Study consortium
(www.onestudy.org) initiated a series of clinical trials to
evaluate cell-based immunotherapies as adjunctive im-
mune modulatory agents in kidney transplantation. The
aim of the ONE Study is to conduct multicenter assess-
ments of the biological effect of regulatory immune cells
on recipient immune responses after transplantation in
comparison to an independent clinical reference group
trial using standard medication at transplant centers
across Europe and the USA. The basic objective of the
ONE Study is to condition the allo-specific immune
response to promote protolerogenic responses to renal
allografts. Different cell types with immune suppressive
characteristics have been described, that are capable of
modulating the allo-reactive immune response following
transplantation [1-4]. Within the ONE Study trials it is
planned to test naturally occurring regulatory T cells
(nTregs) [4-8], type 1 regulatory T (Tr1) cells [1,9-11],
tolerogenic macrophages (Mregs) [2,12,13], and tolero-
genic dendritic cells (DCs) [3,14-16] predominantly for
their safety in renal transplantation, but also for signs of
their ability to prevent biopsy-proven acute rejection
and other transplant-related pathologies, as well as their
biological effects on the recipient. To be able to compare
the effectiveness of these alternative cellular therapeu-
tics, standardization of the immune monitoring assays is
critical. Therefore, the ONE Study consortium de-
veloped a robust immune monitoring procedure to pro-
file peripheral blood cellular phenotype and function of
whole blood (WB) leukocytes based on flow cytometry.
Since the complexity of the immune system requires
the measurement of multiple parameters in parallel and
the characterization of many cell subsets, flow cytometry
has become a very powerful tool for immune diagnostics
[17,18]. However, the assay complexity in combination
with a diversity of equipment, reagents, and many other
pre-analytical factors such as specimen age, staining pro-
cedures, compensation, and analytical factors such as
subset definition, also increases the variability, particu-
larly when comparing results obtained within different
laboratories. The variables that need to be controlled to
ensure standardization have been reviewed elsewhere
and different models for standardization of sample hand-
ling, instrument setup, data acquisition, and data ana-
lysis have been proposed [17-20].
Based on these principles we established robust 7- to
9-color panels for leukocyte profiling capturing the cha-
racteristics of the normal immune phenotype of different
T cell, B cell, and DC subsets, and their activation status.
The ONE Study consortium is using WB as a sample
matrix to capture differences in relative and absolute cellcounts of populations such as neutrophils, plasmablasts,
and DCs, which are removed during peripheral blood
mononuclear cell (PBMC) preparation and freezing. This
approach requires rigorous control of sample collection
and timing of sample preparation.
Here we describe the standardization of leukocyte
profiling by flow cytometry between eight transplan-
tation centers located in Europe and the USA for appli-
cation within the ONE Study. By thorough training that
requires strict adherence to standard operating proce-
dures (SOPs), centrally defining target channels for all
fluorochromes and transferring those to the cytometers
at each site, we achieved comparable results with a low
inter-site variability of 0.05% to 30%, depending on the
frequency of the cell type. This strategy is applicable
for use in multicenter clinical trials, and allows detec-
tion of relative and absolute changes of nearly all blood
leukocyte subsets.
Methods
All procedures were described in SOPs, and the tech-
nical staff at all sites were trained for on-site perfor-
mance of the SOPs.
Blood specimen collection
Healthy individuals were recruited from staff and students
of Charité - Universitätsmedizin Berlin, Berlin, Germany.
Additionally, blood samples from transplant patients
enrolled into the reference trial of the ONE Study were
collected 3 to 6 months after kidney transplantation.
Written informed consent was obtained from all partici-
pants. The study was approved by the Ethics Committee
of the Charité - Universitätsmedizin Berlin.
Blood was collected into vacutainers (BD, Heidelberg,
Germany) containing EDTA for anticoagulation. Anticoa-
gulated peripheral blood for age-of-blood test and inter-
site comparison was stored at 4°C and shipped in 4°C
temperature-controlled boxes. For comparative analysis of
different preservatives, blood was also collected into Cyto-
Chex BCT tubes (Streck labs, Omaha, NE, USA) and
stored at 4°C for the indicated times. All consecutive
blood samples were collected considering the impact of
the circadian rhythm on leukocyte composition and func-
tion, as previously reported [21-24], at similar time points
during the day (± 1 hour).
Antibody panel
Fluorochrome-conjugated anti-human monoclonal anti-
bodies were obtained from Beckman Coulter (Marseille,
France), except anti-BDCA-2 and anti-BDCA-3, which
were obtained from Miltenyi Biotec (Bergisch Gladbach,
Germany), and anti-CCR7, which was obtained from
R&D Systems (Wiesbaden, Germany). Six panel matrices
were defined for 7- to 9-fluorochrome channels.
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at the human leukocyte differentiation antigen (HLDA)
workshops or published results. The fluorochromes for
each antibody were chosen in order to achieve high sensi-
tivity for the detection of dim antigens. Each antibody was
titrated based on achieving the highest signal (mean fluo-
rescence intensity (MFI)) for the positive population and
the lowest signal for the negative population representing
the optimal signal to noise ratio [25]. After optimization,
all panels were formulated at Beckman Coulter. Whenever
a change of the antibody batch occurred, the new formu-
lation was tested against the old one, and was only ac-
cepted when a variability of less than 4% was achieved.
Panel matrices are listed in Additional file 1: Figure S1.
Leukocyte staining
For staining protocol 1, 100 μL of anticoagulated peri-
pheral blood was stained with surface antibodies for 15
minutes at room temperature in the dark prior to lysis
and fixation with VersaLyse + 2.5% IOTest fixative solu-
tion (Beckman Coulter) for 15 minutes in the dark.
Lysed cells were washed twice (PBS, and PBS containing
2% FCS and 0.1% sodium azide) prior to acquisition.
Prepared samples for age-of-stain tests were stored at
4°C. For the investigation of the DC subpopulations,
staining was done twice in parallel to gain sufficient
cell numbers and both samples were combined before
acquisition.
For staining protocol 2, for the investigation of B cell
subpopulations, 300 μL of anticoagulated peripheral
blood was lysed with ammonium chloride (Beckman
Coulter) for 12 minutes at room temperature in rotating
tubes and washed twice with cold PBS. Lysed samples
were stained for 20 minutes at 4°C in the dark, fixed
with 2.5% IOTest fixative solution in PBS for 15 minutes
in the dark, and washed once with PBS containing
2% FCS and 0.1% sodium azide.
The SOPs describing staining protocol 1 and 2
can be found within Additional file 2: Method S6 and
Additional file 3: Method S7.
Cell staining was performed within 30 minutes, or
4 hours and 24 hours after blood collection for the age-
of-blood test. Cell staining for inter-site comparisons
took place simultaneously at all centers 24 or 30 hours
after blood collection.
Data acquisition
All samples were measured on 10 color, 3 laser Navios
flow cytometers (Beckman Coulter) using two different
settings. The first setting was created with anticoagu-
lated peripheral blood samples stained with single anti-
bodies according to staining protocol 1. The second
setting was created using pre-lysed blood stained with
single antibodies according to protocol 2. Both settingsand Navios protocol files were established using a single
Navios at the cytometry laboratory of the Medical Im-
munology at Charité - Universitätsmedizin Berlin. Target
channels were defined for all fluorochromes of both set-
tings using calibration bead particles (Flow-Set Pro beads,
Beckman Coulter) at the same facility. Protocol files and
target channel files were forwarded to all participating
flow cytometry facilities (Figure 1). Settings for all Navios
cytometers were created using the target files in com-
bination with the auto-setup function of the Navios soft-
ware and the same lot of calibration bead particles as used
for the creation of the settings. The relevant SOPs can
be found within the Additional file 2: Method S6 and
Additional file 3: Method S7. The same type of Navios
flow cytometer was used at all participating sites.
Validation test design
For the inter-assay test, blood from four healthy indivi-
duals was collected and assayed on three consecutive
days by two operators. Similarly, for the inter-operator
test, blood from three healthy individuals was collected
and assayed on two consecutive days by two operators.
Within the intra-assay test, the variability in staining re-
sults of blood collected from two healthy individuals and
assayed five times in parallel by one operator was deter-
mined. For the age-of-blood test, blood was taken from
six healthy individuals and assayed at three different
time points (0 hours, 4 hours, 24 hours) after blood col-
lection by one operator. Similarly, in the age-of-stain test
blood was drawn from five healthy individuals, stained
in parallel, and measured at three different time points
(0 hours, 4 hours, 24 hours) by one operator. To com-
pare the reproducibility of the staining between different
sites (inter-site comparison), blood from four healthy
individuals was assayed simultaneously at five centers
30 hours after blood collection by different operators.
Furthermore, to test whether immunosuppressive the-
rapy may impact variability of leukocyte subset identi-
fication, we performed inter-operator tests on samples
collected from transplant patients on three different
days, which were stained by three different operators.
Data analysis
All acquired data files were analyzed by the same analyst
using the Kaluza software, version 1.2 (Beckman
Coulter). Cell doublets were excluded using forward
scatter time of flight (wide) versus forward scatter inte-
gral (area). Leukocytes were gated using CD45 expression
versus side scatter. Absolute counts of the subpopulations
were calculated in all panels by use of the CD45+
leukocyte ‘backbone’ in combination with the WB count
obtained from all samples.
The cell subset definition and the choice of markers
and dyes were discussed and defined within the ONE
Figure 1 Overview of panel design, standardization, and validation within the ONE-Study.
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sensus regarding the applied markers defined the gating
strategy for the data analysis. To ensure correct identifi-
cation of negative and positive cell populations, cells
were plotted using color density bi-exponential displays,
as suggested by Herzenberg et al. [26], except for the
forward and sideward scatter. See also Figures 2, 3, 4, 5,
6, and 7 for the detailed gating strategy of the different
subpopulations.
For the analysis of the inter-assay test, intra-assay test,
and inter-site comparison, a template analysis protocol
was created for each sample and panel. Data files of the
same patient and panel were analyzed by copying the
data files of each time point (inter-assay test) or parallel
staining (intra-assay test, inter-site comparison) into the
appropriate template. Only the sideward scatter (SSC)
parameter was adjusted when necessary for the 24- and
30-hour specimens.
Parameters were exported for the calculation of the
size and frequencies of the subpopulations from the
Kaluza software to Excel (Microsoft, Redmond, WA,
USA). The precision profile approach was used to
characterize the repeatability performance throughout
the range of measurements [42]. Profile is a mathematicalfunction that describes the relationship between the im-
precision of the assay and the measuring range. Means
and coefficients of variation (CVs) were calculated for each
sample. Means of different samples represented the meas-
uring range, while CV represented the corresponding re-
peatability performance. The relationship between mean
and CV throughout the range of measurements was mod-
eled as the repeatability precision profile. A power func-
tion was used to model the profiles. The choice of this
function was based on the best fit of the data as well as
the behavior of the cell counting at different ranges. The
shape of the power function was determined by two pa-
rameters ‘a’ and ‘b’ that were estimated from the data. The
model for the profiles was:
CV i ¼ a Meanib þ ei
where ‘CVi’ and ‘Meani’ were the coefficient of variation
and mean for each i-th sample, ‘a’ and ‘b’ were the pa-
rameters of the model, and ‘ei’ was the random error.
The Gauss–Newton method provided in PROC NLIN
of SAS/STAT 9.3 (SAS Institute, Cary, NC, USA) was
used to obtain the nonlinear least squares estimates of
the parameters and their standard errors.
Figure 2 Overview of the gating strategy for panel ONE 01: general immune phenotype, using the sample of a healthy individual.
The data file of the stained lysed (EDTA spiked) whole blood (WB) was analyzed as follows: exclusion of non-single events (forward scatter time of
flight versus forward scatter integral); gating of CD45+ leukocytes (anti-CD45 versus sideward scatter integral) – the counted CD45+ events were
used as the reference for calculating the absolute cell number of indicated populations in WB; gating and exclusion of granulocytes (anti-CD45
versus sideward scatter integral); gating and exclusion of all CD14+ monocytes (anti-CD14 versus anti-CD64) – the gated CD14+ monocytes were
used to further discriminate different inflammatory/differentiation stages of monocytes (anti-CD16 versus anti-CD14) resulting in CD14++CD16-
classical monocytes, CD14++CD16+ and CD14+CD16++ monocytes, and anti-CD16 versus anti-CD64 to capture CD16+CD64+ monocytes; gating of
lymphocytes (forward scatter integral versus sideward scatter integral); gating of CD56+NK cells, which were further subdivided into CD56dim and
CD56highNK cells; gating of CD3+ T cells (anti-CD56 versus anti-CD3) – gated T cells were used for identification of CD4+ T-cells and CD8+ T-cells
(anti-CD4 versus anti-CD8), and the gated lymphocytes were also used for identification of the B cell population (anti-CD19 versus anti-CD3).
WB, whole blood.
Figure 3 Overview of the gating strategy for panel ONE 02: T cell subsets/αβ+ T cells and γδ+ T cells. The data file of the stained lysed
(EDTA spiked) whole blood (WB) was analyzed as follows: exclusion of non-single events and gating of CD45+ leukocytes as shown for panel ONE
01 (Figure 2); gating of CD3+ T cells (anti-CD3 versus sideward scatter); gating of αβ+ T cells and γδ+ T cells (anti-T cell receptor αβ+ T cells versus
anti-T cell receptor γδ+); and gating of CD4+ and CD8+ T cells for both T cell receptor subsets (anti-CD4 versus anti-CD8). WB, whole blood.
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Figure 4 Overview of the gating strategy for panel ONE 03: T cell activation. Expression of CD57 or HLA-DR and loss of CD27 or CD28
expression was used as a sign of T cell activation, as previously described [27-32]. The data file of the stained lysed (EDTA spiked) whole blood
(WB) was analyzed as follows: exclusion of non-single events and gating of CD45+ leukocytes as shown for panel ONE 01 (Figure 2); gating of
CD3+ T cells (anti-CD3 versus sideward scatter); and gating of CD4+ as well the CD8+ T cells (anti-CD4 versus anti-CD8), for both subsets gating
on CD57+ cells (anti-CD57 versus sideward scatter), HLA-DR+/CD45RA+ (naive, and HLA-DR+/CD45RA- (memory), and CD27-/+ and CD28-/+ subsets
(anti-CD27 versus anti-CD28). WB, whole blood.
Figure 5 Overview of the gating strategy for panel ONE 04: memory T cells and regulatory T cells. The data file of the stained lysed
(EDTA spiked) whole blood (WB) was analyzed as follows: exclusion of non-single events and gating of CD45+ leukocytes as shown for panel ONE
01 (Figure 2); gating of CD3+ T cells (anti-CD3 versus sideward scatter); gating of CD4+ as well the CD8+ T cells (anti-CD4 versus anti-CD8), for
both subsets gating of naive (CCR7+ or CD62L+ and CD45RA+), central memory (CCR7+ or CD62L+ and CD45RA-), effector memory (CCR7- or
CD62L- and CD45RA-), and TEMRA (CCR7- or CD62L- and CD45RA+) subsets, as reported recently [33,34]. CD4+CD25++ were further separated into
CD127low regulatory T cells, discriminating CD45RA+ naive and CD45RA- memory regulatory T cells, and CD127high activated effector T cells [35].
We also enumerated activated CD8+CD25++ cells. WB, whole blood.
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Figure 6 Overview of the gating strategy for panel ONE 05: B cell subsets. Identification of B cell subsets was based on previously published
classifications [36,37]. The data file of the stained lysed (EDTA spiked) whole blood (WB) was analyzed as follows: exclusion of non-single events and gating
of CD45+ leukocytes as shown for panel ONE 01 (Figure 2); gating of CD19+ B cells (anti-CD19 versus sideward scatter); gating of CD21low B cells (anti-
CD38 versus anti-CD21); gating of IgD-IgM- and IgM+ B cells (anti-IgD versus anti-IgM). Pre-gated IgD-IgM- B cells were further used to identify plasmablasts
(CD27+CD38high) and class-switched memory B cells (CD27+CD38low), pre-gated IgM+ B cells were used to identify of class non-switched memory B cells
(CD27+CD38low), and the pre-gated IgM+CD27- B cells were used to identify transitional B cells (CD24+CD28high). WB, whole blood.
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of the measuring range. We will refer to this limit as the
lower limit of quantitation (LoQ) [43]. LoQ was the low-
est limit of the measuring range where the leukocyte
subpopulation was determined within an acceptable level
of imprecision. We chose to represent imprecision by
different target CV values, as shown in Figure 8.Figure 7 Overview of the gating strategy for panel ONE 06: dendritic
previously reported [38-41]. The data file of the stained lysed (EDTA spiked
events and gating of CD45+ leukocytes as shown for panel ONE 01 (Figure
anti-CD56) negative HLA-DR+ cells, identification of LIN-HLA-DR+CD11c+ m
anti-HLA-DR). Pre-gated mDCs were used to identify CD16+, mDC1, and BD
to identify plasmacytoid DCs (CD123+BDCA2+). DC, dendritic cell; mDC, myThe solution for estimating LoQ from the precision
profile using different target CV values (Target_CV) was
as follows:
LoQ ¼ exp






5cell (DC) subsets. DCs and their subpopulations were identified, as
) whole blood (WB) was analyzed as follows: exclusion of non-single
2); gating of lineage (LIN; anti-CD3, anti-CD14, anti-CD19, anti-CD20,
yeloid DCs (mDCs), and LIN-HLA-DR+CD11c- cells (anti-CD11c versus
CA3+mDC subsets, and pre-gated LIN-HLA-DR+CD11c- cells were used
eloid dendritic cell; LIN, lineage; WB, whole blood.
Figure 8 Single CV values of all cell subsets tested within intra-assays (whole blood (WB) material from two healthy individuals;
71 single subsets = 142 data points). CV values include five replicates assayed in parallel. Shown are the function, regression, and 95%
confidence interval of the CV versus counted events, CV versus calculated absolute cell number of the gated subpopulations, and CV versus
percentage of the gated subpopulation. Also shown are the calculated lower limits of quantitation (LoQ) and the upper LoQ for a given CV.
CV, coefficient of variation; LoQ, limit of quantitation; WB, whole blood.
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standard error of LoQ. The upper confidence limits were
based on the standard error of LoQ and 95% confidence
interval.
Results
Panel setup and optimization of staining procedure
The immune response towards allogeneic transplants in-
volves activation and alterations of leukocytes from both
the adaptive and the innate immune system [44-48]. Fur-
thermore, comparative analysis of peripheral blood fromoperationally tolerant and non-tolerant patients has re-
vealed differences in the composition of, for example,
regulatory T cells, memory B cells, but also γδ T cells
and NK cells [44,49-52]. Thus, we designed six 7- to
9-color flow panels that allow the capture of frequencies,
numbers, differentiation, and activation of nearly all
described blood leukocyte subsets (see also Figures 2, 3,
4, 5, 6, and 7, and Additional file 1: Figure S1).
To avoid alterations in leukocyte composition and
activation, which can occur upon PBMC isolation, and
to ensure comparability between centers, staining was
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as simple as possible. This resulted in a single protocol
for surface staining and for setting compensation of five
of the six staining panels, as outlined in the Methods
section.
Examination of B cell subpopulations in panel ONE 05
required that free immunoglobulins in the plasma were
removed by washing prior to staining of surface IgD and
IgM. This washing step was combined with pre-staining
erythrocyte lysis, which also ensured the enrichment and
subsequent staining of low abundance cells such as plas-
mablasts and transitional B cells. The pre-washing step
was necessary as free immunoglobulins in the serum
particularly affect surface staining of IgM and IgD, as
shown in Additional file 4: Figure S2.
The gated defining negative and positive leukocyte sub-
populations for each surface marker were set using color
density bi-exponential displays, as also recommended by
others [26], except when displaying the cells according
to their scatter signals. All together, the staining proce-
dures described here and the presented gating strategy
(Figures 2, 3, 4, 5, 6, and 7) allowed for good discrimi-
nation of all target leukocyte populations using fresh
WB material of healthy individuals.
Precision, robustness, and biological variability
To evaluate the precision of the test system, intra-assay,
inter-assay, and inter-operator tests were performed, and
the CVs of percent positive cells and absolute cell counts
were calculated. A fixed template for gating on leukocyte
subsets and defining true positive subpopulations was
used to improve standardization of the analysis system.
The CV for the intra-assay test with five assay replicates
per WB sample allowed an analysis of the tube-to-tube
consistency. The replicate tube was assayed in parallel,
and the intra-assay CV was calculated from the relative
values, the counted event numbers, and the absolute cell
number for each population (Figure 9).
At least 142 single CVs of 71 subpopulations were
included in the analysis (Figures 8 and 9). Comparing the
relative counts for the gated populations (that is, percen-
tages), only three cell populations from the 71 total popu-
lations exceeded a CV of 20%. Furthermore, only 12 cell
populations had a CV of greater than 10%. Similar results
were obtained when calculating the CV for absolute cell
numbers. Five populations showed a CV above 20%, and
20 populations a CV above 10%. CV values calculated for
the percentages of all lineage markers (CD45, CD3, CD4,
CD8, CD19, CD56) were below 4%, except for the mono-
cytes, which had a mean CV of 7.5%.
The inter-operator CV was calculated as outlined for
the intra-assay test. Mean CVs were compared to the
calculations of the intra-assay test; more than 80% of the
CVs varied by less than 1% (Figure 10). Considerableincreases in inter-operator CVs, as compared to intra-
assay CVs, were observed for the monocytes and their
subpopulations, which was independent of the size of
the populations or the number of counted events. To
test whether immunosuppressive therapy may impact
variability of leukocyte subset identification, we per-
formed inter-operator tests on samples collected from
transplant patients on three different days, which were
stained by three different operators. Importantly, all spe-
cified leukocyte subpopulations could be identified in
the blood of immunosuppressed transplant patients. Fur-
thermore, the determined variability of individual sub-
sets was nearly identical as compared to values detected
by staining blood collected from healthy volunteers
(Additional file 5: Figure S3).
Inter-assay variability was determined by staining cells
from four healthy individuals on three consecutive days.
The mean CVs of the inter-assay test were up to 12%
greater than the CVs of the intra-assay for the majority
of cell populations (Figure 9). This is consistent with
previous observations that the biological variability in a
WB test with fresh blood donations over several con-
secutive days is significantly greater than classical inter-
assay variability, at which the same sample is stained on
three consecutive days [46]. For some leukocyte subsets
such as CD4+CD28- T cells, plasmablasts, or MDC2
DCs, higher CVs (up to 30%) were observed due to the
small population size (lower event counts). Only the CV
values for the monocyte subpopulations increased simi-
larly to the inter-operator test, regardless of population
size. Stabilizing blood collection devices (for example,
Cyto-Chex blood collection tubes) could not be used to
reduce inter-assay variability, as they affect expression of
some surface markers such as CD62L and CCR7 on T
cells, and particularly IgM on B cells (Additional file 6:
Figure S4). Therefore, inter-assay data was excluded from
the precision and LoQ estimations, as described later on
(Figure 8).
Stability of collected material and stained samples
The variability as a result of blood specimen age prior to
staining was estimated by the age-of-blood test. The varia-
bility for a change from baseline (0 hours) of 4 hours
ranged up to 65% for some gated populations, compared
to immediate staining after blood collection. Again,
variability was highest in low-abundant cell populations
such as plasmablasts (CV of 65%). Thus the change from
baseline variability negatively correlates with the WB fre-
quency or absolute cell count.
Within the 4-hour window, a small amount of variability
was observed for all lineage markers and T cell subsets
(up to 10%), whereas the variability for the monocyte,
B cell, and DC subpopulations increased by up to more
than 20%. Performing the staining at 24 hours after blood
Figure 9 Mean CVs of cell subsets tested in intra-assay test, inter-operator-test, and inter-assay test, and also the change from
baseline for the age-of-stain test 4 hours + 24 hours and the age-of-blood test 4 hours + 24 hours for all six panels. Panel ONE 01,
general immune status; panel ONE 02, T cell subsets/αβ+ T cells and γδ+ T cells; panel ONE 03, T cell activation; panel ONE 04, T cell memory and
regulatory T cells; panel ONE 05, B cell subsets; and panel ONE 06, dendritic cell (DC) subsets. CV, coefficient of variation; DC, dendritic cell.
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Figure 10 Mean CVs of cell subsets tested in inter-operator test and inter-laboratory test for all six panels. Panel ONE 01, general
immune status; panel ONE 02, T cell subsets/αβ+ T cells and γδ+ T cells; panel ONE 03, T cell activation; panel ONE 04, T cell memory and
regulatory T cells; Panel ONE 05, B cell subsets; and panel ONE 06, dendritic cell (DC) subsets. CV, coefficient of variation; DC, dendritic cell.
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especially for the aforementioned critical populations,
which in some cases reached excessive values ofup to 200%. Thus, staining of WB samples within
4 hours of collection is of utmost importance for
reliable results.
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leukocyte subsets following a time delay of 4 hours bet-
ween sample staining and measurement. We observed
very little variability with small CVs for most parameters,
which again correlated with the number of counted
events and percentages of gated populations (Figure 9).
Variability of infrequent populations increased slightly
following a time delay of 24 hours between staining and
measurement. Significant differences were found again
only for monocyte subpopulations.
Reproducibility test by inter-site comparison
To evaluate the reproducibility between participating
sites, inter-site comparisons were performed. Different
time points for the first enrollment of patients at diffe-
rent ONE Study sites meant that this test was performed
several times, but always included different participating
sites. Here we show the results of two inter-site compa-
risons between three laboratories within Europe for the
first comparison, and between five laboratories in
Europe and one in the USA for the second comparison.
The second inter-laboratory comparison posed a par-
ticular challenge due to the long shipment time of WB
samples from Berlin to San Francisco. The specimen age
stability data described above meant that there was an
expected impact due to the age of the blood specimen.
Assays were performed simultaneously according to the
standard SOPs at all sites. Due to shipment, staining was
started 24 hours after blood collection for the first inter-
site comparison and 30 hours after blood collection in
case of the second test. Overall CVs below 15% were ob-
tained for 66% of the parameters (Figure 10). Similar to
the other variability tests, significant increases were ob-
served in the CVs for the monocyte subpopulations, and
rather infrequent B cell (transitional B cells and plas-
mablasts), DC, and CD4+CD25high T cell populations.
The original data of all validation tests are given within
Additional file 7: Figure S5.
Defining limits of quantitation (LoQ)
Since the biological variability of blood collected on
three consecutive days, as it was done for the inter-assay
variability test, can be quite high and does not corres-
pond to a classical inter-assay test, the results of the
intra-assay evaluation were used to calculate the LoQ
and 95% confidence interval (see Methods section).
When plotting CVs versus the percentages, absolute
numbers and counted events for each leukocyte subpo-
pulation revealed increasing CVs as a function of all
three parameters (Figure 8). We detected increased CV
values with a decreased number of counted events, ab-
solute cell numbers, and acquired numbers of cells in
leukocyte subpopulations. Therefore, it is impossible to
define the same cut-off value for the CV of all leukocytesubsets. We rather calculated the lower (LoQ) and upper
limits of absolute cell counts, frequencies, or acquired
events for a given target CV using the power function
described within the Methods (Figure 8). Accordingly, a
leukocyte subpopulation occurring with a frequency of
0.5% per all CD45+ leukocytes can be identified and
quantified assuming a CV of up to 15%. All subpopula-
tions met these LoQ criteria except for two monocyte
subpopulations (CD16+CD64+ and CD14highCD16+), and
the CD4+CD25high subpopulation. This function of CVs
will also ensure a reliable definition of significant diffe-
rences observed for a subset between patient popula-
tions. Changes in leukocyte subsets between patient
populations will need to be equal or higher to the corre-
sponding CV calculated by the function.
Discussion
As the precision of flow cytometric profiling of WB
samples is impacted by many variables, standardization
becomes crucial for use when immune monitoring
within clinical trials. For the immune monitoring of
transplant patients within the ONE Study, we defined
six flow cytometry panels that are being used to stain
WB samples locally at all participating clinical sites,
followed by a central gating and leukocyte subset ana-
lysis, as previously recommended [17,19,26,53]. The
results of the performance evaluation of the panels des-
cribed here demonstrate highly reproducible SOPs that
are applicable in general for use in multicenter clinical
trials.
We detected low variability in leukocyte subset fre-
quency and absolute counts between different local
laboratories for the majority of the leukocyte cell sub-
populations, especially for the T cell subsets. Although
more variable, monocyte subsets and certain subsets of
DCs and B cells show acceptable variability of up to
30%. While the affected DC and B cell subsets encom-
pass small populations with low absolute cell counts that
contribute to higher variability, monocyte subsets show
higher variability independent of population size or ab-
solute cell count. Nonetheless, we are now able to define
limits for statistically significant relative and absolute
changes between patient cohorts for the leukocyte sub-
sets as defined by intra-assay (Figures 8 and 9) and
inter-operator variability, which is highly dependent on
the subset abundance, as previously reported [53]. Ap-
plying the developed function for target CVs in relation
to, for example, cell frequency, observed differences for
a leukocyte subset between two patient populations can
only reach significance if those differences are higher
than the calculated CV. Thus, a leukocyte population
occurring on average at a frequency of 0.5% can only
change significantly if an increase or decrease by at least
15% is detected.
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was not only achieved when staining samples collected
from healthy volunteers, but also with samples from
kidney transplant recipients on immunosuppressive
therapy. This clearly shows the feasibility of the staining
protocols for use in multicenter clinical trials enrolling
kidney transplant patients.
There are many possible reasons for exceptional be-
havior of monocytes and their subsets, and difficulties in
standardized enumeration of monocytes have been re-
ported previously [54,55]. Due to their inherent nature,
monocytes tend to adhere to plastic surfaces, which may
become more relevant with a longer storage time. How-
ever, while this can explain the variability observed due
to specimen age and inter-site comparisons with aged
(24- and 30-hour) blood, it does not explain the in-
creased variability detected within inter-assay and inter-
operator comparisons.
Considering all factors, including the feasibility of a
minimal time delay between blood collection/processing,
and our observed alterations in determined subset fre-
quency and count, we defined a time window of 4 hours
for WB staining. By doing so, an acceptable variability
of below 30% is achievable for most cell populations,
except for infrequent populations such as plasma blasts
or certain monocyte subpopulations.
It has been reported by several groups that perhaps the
largest single contributor to variability in flow cytometry
is the difference in gating the target leukocyte populations
[17-19,56]. To control for such alteration, a centralized
gating and target definition strategy was chosen. This
strategy corresponds to the ‘mixed model’ reported by
Maecker et al. [17], in which samples are supposed to be
obtained, processed, and acquired at local sites through
the use of strict SOPs, with a central laboratory perfor-
ming the analysis of acquired flow cytometry files.
To avoid misclassification of negative and positive
leukocyte subsets, and thus misinterpretation of the re-
sults, which can easily happen within multicenter clinical
trials, we based the gating strategy nearly completely on
color density bi-exponential displays. Furthermore, fol-
lowing panel establishment and optimization, a template
analysis protocol for the gating strategy was created for
each panel, approved by all sites, and subsequently used
for the analysis of all files. Only in the case of the
24-hour age-of-blood and inter-site comparisons did the
pre-defined gates have to be slightly modified. This was
due to alterations in forward and side scatter positions
of individual leukocyte subsets upon prolonged WB sto-
rage (24 and 30 hours in case of inter-site comparisons).
During the trial, specimen age will be strictly controlled
to less than 4 hours before staining, so this gating
change will not be needed and will not impact patient
sample analysis.In summary, our defined flow cytometry panels allow
enumeration of the abundance and activation of a large
number of leukocyte subsets with a high precision across
multiple international sites. Using this standardized
strategy of leukocyte profiling to identify changes in
leukocyte subsets, we propose that it will be feasible to
detect effects of immunomodulatory treatments within
and between multicenter clinical trials. Therefore, this
operating procedure will not only be useful in the con-
text of the ONE Study trials, it could also be applied to
other clinical trials where sensitive immune monitoring
provides valuable information. Equally important, the
sharing of procedures and protocols for flow cytometry
will allow for more reliable comparisons of immuno-
logical effects between these different clinical trials.
Additional files
Additional file 1: Figure S1. Panel matrix for flow cytometry-based
immune monitoring within the ONE Study. Listed are all antibodies with
clone ID and fluorochrome conjugate.
Additional file 2: Method S6. Method describing the standard
operating procedure for staining of whole blood leukocytes with panel
ONE 01, 02, 03, 04, 06.
Additional file 3: Method S7. Describing the standard operating
procedure for staining of whole blood leukocytes with panel ONE 05.
Additional file 4: Figure S2. Exemplary dot plots for surface IgM
staining on CD19+ B cells comparing whole blood (WB) staining with and
without prior removal of free plasma immunoglobulins by an ammonium
chloride-based lyse/wash step.
Additional file 5: Figure S3. Mean CVs of cell subsets were calculated
in inter-operator test on samples collected from transplant patients 3 to 6
months after kidney transplantation for all six panels: panel ONE 01,
general immune status; panel ONE 02, T cell subsets/αβ+ T cells and γδ+
T-cells; panel ONE 03, T cell activation; panel ONE 04, T cell memory and
regulatory T cells; panel ONE 05, B cell subsets; and panel ONE 06,
dendritic cell (DC) subsets.
Additional file 6: Figure S4. Comparative analysis of leukocyte staining
of whole blood (WB) samples collected into EDTA or Cyto-Chex tubes.
Shown are dot plots of CCR7 versus CD45RA, and CD62L versus CD45RA
staining for CD4+ T cells using the same gating strategy as described in
Figure 5. Additionally IgM versus IgD staining of CD19+ B cells is
displayed applying the same gating strategy as described in Figure 6.
Additional file 7: Figure S5. Shown are all results for the validation of
the flow cytometry immune monitoring for the ONE Study, including all
single CVs and mean CVs, respectively, and all changes from baseline and
mean changes from baseline for all test assays.
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